Chinook Therapeutics
(NASDAQ) KDNY
This security has been delisted. This page is retained for historical reference.
KDNY News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowKDNY Financials
Key Financial Metrics (TTM)
Gross Margin
72%
Operating Margin
-30%
Net Income Margin
-30%
Return on Equity
-41%
Return on Capital
-35%
Return on Assets
-32%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$4.41M
Operating Income
$185.08M
EBITDA
$164.20M
Operating Cash Flow
$117.48M
Capital Expenditure
$1.65M
Free Cash Flow
$119.13M
Cash & ST Invst.
$378.32M
Total Debt
$39.44M
Chinook Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$1.01M
+141.1%
Gross Profit
$575.00K
+5327.3%
Gross Margin
57.04%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
214
N/A
Net Income
$66.94M
-77.8%
EBITDA
$69.90M
-77.5%
Quarterly Fundamentals
Net Cash
$263.18M
-17.9%
Accounts Receivable
$3.10M
-0.4%
Inventory
$0.00
N/A
Long Term Debt
$29.72M
-20.0%
Short Term Debt
$4.27M
-9.2%
Return on Assets
-32.16%
N/A
Return on Invested Capital
-35.37%
N/A
Free Cash Flow
$61.81M
-100.4%
Operating Cash Flow
$61.20M
-99.9%